...
首页> 外文期刊>Journal of plastic, reconstructive & aesthetic surgery: JPRAS >Treatment of muscular contraction deformities with botulinum toxin type A after latissimus dorsi flap and sub-pectoral implant breast reconstruction.
【24h】

Treatment of muscular contraction deformities with botulinum toxin type A after latissimus dorsi flap and sub-pectoral implant breast reconstruction.

机译:背阔肌皮瓣和胸下植入物重建乳房后,用A型肉毒杆菌毒素治疗肌肉收缩畸形。

获取原文
获取原文并翻译 | 示例

摘要

Unusual and probably underestimated complications following breast reconstruction with a latissimus dorsi (LD) flap and sub-pectoral implant are the LD muscle twitching and the breast contour deformities from pectoralis major (PM) muscle contraction. Surgical muscle denervation is usually indicated for these complications. Botulinum toxin A (BTX-A) infiltration has been described in reducing breast contour deformity in sub-pectoral implant after breast augmentation or reconstruction. Between January 2002 and April 2006, 71 consecutive patients underwent delayed unilateral breast reconstructions with LD flap and sub-pectoral implant after mastectomy. All patients reporting discomforting signs and symptoms from muscle contraction in the reconstructed breast were included in this prospective study. Thirteen patients (18.3%) were selected and treated with BTX-A percutaneous local injections. Signs and symptoms were evaluated, after 4, 8 and 12 months, by the patients and by a panel of three physicians not involved in the study, using a five-point scale. During the study period all patients reported a decrease or disappearance of the signs and symptoms. After 12 months, 11 patients received three BTX-A infiltrations, demonstrating considerable improvements compared to the pre-treatment status. Wilcoxon matched pairs rank sum test showed a statistical difference between pre-treatment and post-treatment scores after 14 days (P<0.01) and 12 months (P<0.001). Our experience shows that muscular contraction deformities after breast reconstruction with a LD flap plus implant are not uncommon complications. The use of BTX-A infiltrations is an effective, not surgical, low cost and low risk procedure to treat these complications. It is an easy procedure to be performed on an outpatient basis with a temporary effect but safely repeatable and reproducible; it avoids hospitalisation or further surgical procedures and demonstrates tolerable latency with satisfactory outcomes.
机译:背阔肌(LD)皮瓣和胸下植入物重建乳房后出现的异常和可能被低估的并发症是LD肌肉抽搐和胸大肌(PM)收缩引起的乳房轮廓变形。对于这些并发症,通常需要手术神经去神经支配。肉毒杆菌毒素A(BTX-A)浸润已被描述为减少隆胸或重建后的胸下植入物的乳房轮廓变形。在2002年1月至2006年4月之间,连续71例患者在乳房切除术后接受了LD皮瓣和胸膜下植入物的延迟单侧乳房再造。这项前瞻性研究包括所有报告了乳房再造过程中肌肉收缩引起不适迹象和症状的患者。选择了13例患者(18.3%)并接受BTX-A经皮局部注射治疗。在4、8和12个月后,由患者以及由三名未参与研究的医师组成的小组使用五点量表对症状和体征进行评估。在研究期间,所有患者均报告症状和体征减少或消失。 12个月后,有11名患者接受了3次BTX-A浸润,与治疗前相比有明显改善。 Wilcoxon配对配对秩和检验显示14天(P <0.01)和12个月(P <0.001)后治疗前和治疗后评分之间的统计学差异。我们的经验表明,使用LD皮瓣加植入物重建乳房后的肌肉收缩畸形并不罕见。 BTX-A浸润是治疗这些并发症的有效,非手术,低成本和低风险的方法。这是在门诊病人上执行的简便程序,具有暂时效果,但可以安全地重复和重现;它避免了住院或进一步的手术程序,并显示出可忍受的潜伏期和令人满意的结果。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号